AnthonyHunterMD
Hematology • Atlanta, GAHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Assistant Professor, Emory University School of Medicine, Winship Cancer Institute
Dr. Hunter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1365 Clifton Rd NE
Atlanta, GA 30322Phone+1 404-778-1900
Education & Training
University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2017 - 2020
Emory University School of MedicineResidency, Internal Medicine, 2014 - 2017
Medical College of WisconsinClass of 2014
Certifications & Licensure
GA State Medical License 2020 - 2025
FL State Medical License 2017 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.Elias Jabbour, Vivian G Oehler, Paul B Koller, Omer Jamy, Elza Lomaia
JAMA Oncology. 2024-11-21 - Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.Anthony M Hunter, Mrinal M Patnaik, Raphael Itzykson, Ruben Mesa, Chatchada Karanes
Blood. 2024-11-07 - SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis.Michael J Hochman, Colin A Vale, Anthony M Hunter
Clinical Lymphoma, Myeloma & Leukemia. 2024-09-12
Abstracts/Posters
- Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell TransplantationAnthony Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study ...Anthony M. Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic LeukemiaAnthony Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
A Legacy of TyrosineMay 11th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
